Veradermics (MANE) CTO Timothy Durso Sells Shares After Exercising Options

What Happened Timothy Durso, Chief Technical Officer of Veradermics, exercised options and sold shares on August 17, 2026. The Form 4 shows an exercise (code M) acquiring 3,452 shares at $12.19 for $42,080, and multiple open-market sales totaling 43,500 shares for aggregate proceeds of approximately $4,690,004. The sales broke down as:

• 7,918 shares sold at a weighted avg $106.71 — $844,930 (range $106.25–$106.99)
• 16,306 shares sold at a weighted avg $107.52 — $1,753,221 (range $107.00–$107.99)
• 16,767 shares sold at a weighted avg $108.38 — $1,817,207 (range $108.00–$108.99)
• 2,348 shares sold at a weighted avg $109.34 — $256,730 (range $109.00–$109.96)
• 161 shares sold at $111.28 — $17,916
  The filing also reports a derivative disposition of 3,452 shares at $0.00 (code M), which commonly reflects surrender or netting of option shares related to the exercise or tax withholding.

Key Details

• Transaction date: August 17, 2026; Form 4 filed Aug 18, 2026 (timely).
• Total sold: 43,500 shares for ≈ $4.69 million; total cash paid to exercise options: $42,080.
• Footnotes: weighted-average sale prices reported with price ranges (see F1–F4); note F5 states the option was fully vested and exercisable. The reporting person offers to provide per-price breakdowns on request.
• Shares owned after the transactions: not provided in the data you supplied.

Context

• This was an option exercise followed by substantial open-market selling. When filings show an exercise immediately followed by sales (and a $0 disposition line), it often reflects a cashless/net exercise or share surrender to satisfy exercise cost/taxes, but the Form 4 itself does not state the insider’s motive.
• Sales are common for insiders for liquidity or tax reasons; purchases are generally viewed as a stronger bullish signal. This filing documents sizable proceeds but does not alone indicate company outlook.